Related Experiment Video
Updated: Apr 8, 2026

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
Published on: July 30, 2020
Aurora kinase inhibition: a new light in the sky?
Spiros Linardopoulos1,2, Julian Blagg1
1†Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K.
Abstract:
The quest for potent and selective small molecule inhibitors of the Aurora kinases has been long and resource intensive with multiple agents progressed to the clinic. To definitively explore the potential for clinical efficacy at well-tolerated dosing schedules requires a well-characterized, selective inhibitor with pharmacokinetic properties, flexible dosing regimen, and suite of target engagement biomarkers suitable for clinical use. AMG900 is a promising opportunity to definitively test the clinical benefit of dual Aurora kinase A and B inhibition.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
Anaphase Promoting Complex
cAMP-dependent Protein Kinase Pathways

